CVS Health: One Good Quarter Is Not Enough; Retain Sell (Archive)

This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.

Elevator Pitch

• Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage levels.
• CVS' Q4 results showed a surprising EBIT margin beat, but continued margin erosion in its insurance business remains a concern.
• Improved margin performance in FY25 is possible with better insurance policy terms and reduced loss-making membership counts but given a poor execution record, it is better to wait for evidence.
• Transparent pricing via the CostVantage pricing model may boost volumes in the pharmacy business in FY25.
• Valuations vs comps are at a lower than usual discount and technical analysis suggests a likely bull trap. Leverage levels are also climbing. All this warrants caution.

Read the full article here.